Russia's breast cancer drug market will reach $226 million by 2014

The breast cancer drug market in Russia will reach a value of $226 million by 2014, according to forecasts by advisory firm Decision Resources. Factors promoting the market's growth include steady increases in the incidence of post-menopausal breast cancer cases, a slight shift toward higher-cost chemotherapy regimens and increases in the use of targeted therapies following novel premium-priced product launches in the larger non-hormonal segment of the market, the report predicts.

"In 2009, branded drugs accounted for approximately 81% of total sales ' 80% of non-hormonal drug sales and 82% of hormonal drug sales," stated Decision Resources' analyst Natalia Reoutova. "Increasing competition from generics over our 2009-2014 study period will not affect multinational companies' share of non-hormonal agents due to the anticipated launch of new therapies. However, the impact will be greater in the hormonal breast cancer therapy market, where multinational companies' sales share will decrease from 82% to 67% in 2014," she added.

Novel agents expected to drive growth